Item request has been placed!
×
Item request cannot be made.
×
Processing Request
[One step towards restoration of self-tolerance in human autoimmune diseases].
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Chatenoud L;Chatenoud L
- Source:
Medecine sciences : M/S [Med Sci (Paris)] 2007 Feb; Vol. 23 (2), pp. 167-71.
- Publication Type:
Journal Article; Review
- Language:
French
- Additional Information
- Transliterated Title:
Une étape vers la restauration de la tolérance immunitaire au soi dans les maladies auto-immunes humaines.
- Source:
Publisher: EDK Country of Publication: France NLM ID: 8710980 Publication Model: Print Cited Medium: Print ISSN: 0767-0974 (Print) Linking ISSN: 07670974 NLM ISO Abbreviation: Med Sci (Paris) Subsets: MEDLINE
- Publication Information:
Publication: <2003->: Paris : EDK
Original Publication: [Paris] : Flammarion, [1985-
- Subject Terms:
Autoantigens/
*therapeutic use ;
Autoimmune Diseases/
*therapy ;
Diabetes Mellitus, Type 1/
*therapy ;
Immunotherapy/
*methods ;
Self Tolerance/
*immunology;
Adult ;
Animals ;
Antibodies, Monoclonal/
immunology ;
Antibodies, Monoclonal/
therapeutic use ;
Antibodies, Monoclonal, Humanized ;
Autoantibodies/
biosynthesis ;
Autoantibodies/
immunology ;
Autoantigens/
immunology ;
Autoimmune Diseases/
immunology ;
Autoimmunity/
immunology ;
CD3 Complex/
immunology ;
Chaperonin 60/
immunology ;
Chaperonin 60/
therapeutic use ;
Clinical Trials, Phase I as Topic ;
Clinical Trials, Phase II as Topic ;
Clonal Deletion ;
Diabetes Mellitus, Type 1/
immunology ;
Glutamate Decarboxylase/
immunology ;
Glutamate Decarboxylase/
therapeutic use ;
Humans ;
Immunoglobulin G/
immunology ;
Immunoglobulin G/
therapeutic use ;
Infant, Newborn ;
Insulin/
immunology ;
Insulin/
therapeutic use ;
Islets of Langerhans/
immunology ;
Mice ;
Mice, Inbred NOD ;
Muromonab-CD3/
immunology ;
Muromonab-CD3/
therapeutic use ;
Randomized Controlled Trials as Topic ;
T-Lymphocyte Subsets/
immunology ;
Thymectomy/
adverse effects - Abstract:
In developed countries the incidence of autoimmune insulin-dependent or type 1 diabetes as the one of all autoimmune diseases has steadily increased over the last decades. Conventional therapy of type 1 diabetes is essentially palliative namely, chronic delivery of exogenous insulin that is associated with major constraints (multiple daily parenteral administration, serious risks linked to hypoglycemic episodes) and incomplete effectiveness in preventing severe degenerative complications. This explains the growing attention on modern therapeutic strategies using biological agents such as CD3 monoclonal antibodies that allow 'reprogramming' the immune system to restore self-tolerance to pancreatic beta cell antigens. This strategy which proved successful in the experimental setting has recently been translated to the clinic with very encouraging results. CD3 antibodies may represent a new category of drugs affording a real cure for autoimmunity namely, inhibiting the pathogenic immune response while preserving the host reactivity to unrelated antigens.
- Number of References:
42
- Accession Number:
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Autoantibodies)
0 (Autoantigens)
0 (CD3 Complex)
0 (Chaperonin 60)
0 (Immunoglobulin G)
0 (Insulin)
0 (Muromonab-CD3)
EC 4.1.1.15 (Glutamate Decarboxylase)
S4M959U2IJ (teplizumab)
- Publication Date:
Date Created: 20070213 Date Completed: 20070702 Latest Revision: 20171116
- Publication Date:
20231215
- Accession Number:
10.1051/medsci/2007232167
- Accession Number:
17291426
No Comments.